Clinically Available Medicines Demonstrating Anti-Toxoplasma Activity
暂无分享,去创建一个
P. Davis | Xiaofang Wang | J. Vennerstrom | L. Davis | S. Zach | A. Neville | J. Larson | A. Judge
[1] S. Costa,et al. Current Therapy of Acquired Ocular Toxoplasmosis: A Review , 2015 .
[2] L. Younis,et al. Could miltefosine be used as a therapy for toxoplasmosis? , 2015, Experimental parasitology.
[3] M. Leboyer,et al. Beyond the association. Toxoplasma gondii in schizophrenia, bipolar disorder, and addiction: systematic review and meta‐analysis , 2015, Acta psychiatrica Scandinavica.
[4] M. Hakimi,et al. Structure of Prolyl-tRNA Synthetase-Halofuginone Complex Provides Basis for Development of Drugs against Malaria and Toxoplasmosis. , 2015, Structure.
[5] Scott Emrich,et al. A molecular mechanism of artemisinin resistance in Plasmodium falciparum malaria , 2015, Nature.
[6] H. Ramadan,et al. Triclosan and triclosan-loaded liposomal nanoparticles in the treatment of acute experimental toxoplasmosis. , 2015, Experimental parasitology.
[7] R. Y. Othman,et al. Recent Advances in Toxoplasma gondii Immunotherapeutics , 2014, The Korean journal of parasitology.
[8] L. A. Veloza,et al. Anti-Toxoplasma activity of natural products: a review. , 2014, Recent patents on anti-infective drug discovery.
[9] J. E. Bennett,et al. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases , 2014 .
[10] Zhaoshou Yang,et al. Gefitinib Inhibits the Growth of Toxoplasma gondii in HeLa Cells , 2014, The Korean journal of parasitology.
[11] Juan D. Chaparro,et al. Auranofin Is Highly Efficacious against Toxoplasma gondii In Vitro and in an In Vivo Experimental Model of Acute Toxoplasmosis , 2014, PLoS neglected tropical diseases.
[12] K. Andrews,et al. Drug repurposing and human parasitic protozoan diseases , 2014, International journal for parasitology. Drugs and drug resistance.
[13] M. Leboyer,et al. Comparative analysis of anti-toxoplasmic activity of antipsychotic drugs and valproate , 2014, European Archives of Psychiatry and Clinical Neuroscience.
[14] L. Knoll,et al. Fusidic acid is an effective treatment against Toxoplasma gondii and Listeria monocytogenes in vitro, but not in mice , 2013, Parasitology Research.
[15] D. Rice,et al. Modification of Triclosan Scaffold in Search of Improved Inhibitors for Enoyl‐Acyl Carrier Protein (ACP) Reductase in Toxoplasma gondii , 2013, ChemMedChem.
[16] J. Flegr. How and why Toxoplasma makes us crazy. , 2013, Trends in parasitology.
[17] H. Atmaca,et al. In-vivo efficacy of toltrazuril on experimentally induced Toxoplasma gondii tissue cysts in lambs: a novel strategy for prevention of human exposure to meat-borne toxoplasmosis. , 2013, Research in veterinary science.
[18] W. de Souza,et al. Toxoplasma gondii: the effect of fluconazole combined with sulfadiazine and pyrimethamine against acute toxoplasmosis in murine model. , 2013, Experimental parasitology.
[19] Y. Alfonso,et al. Antiretroviral activity of protease inhibitors against Toxoplasma gondii. , 2013, Revista do Instituto de Medicina Tropical de Sao Paulo.
[20] P. Khanna,et al. Development of Toxoplasma gondii vaccine , 2012, Human vaccines & immunotherapeutics.
[21] C. Roberts,et al. Salicylanilide inhibitors of Toxoplasma gondii. , 2012, Journal of medicinal chemistry.
[22] N. M. Silva,et al. Enrofloxacin is able to control Toxoplasma gondii infection in both in vitro and in vivo experimental models. , 2012, Veterinary parasitology.
[23] J. Haagsma,et al. Disease burden of foodborne pathogens in the Netherlands, 2009. , 2012, International journal of food microbiology.
[24] P. Davis,et al. Toxoplasma on the Brain: Understanding Host-Pathogen Interactions in Chronic CNS Infection , 2012, Journal of parasitology research.
[25] Leann Tilley,et al. Artemisinin activity against Plasmodium falciparum requires hemoglobin uptake and digestion , 2011, Proceedings of the National Academy of Sciences.
[26] D. Lindsay,et al. Evaluation of Five Antischizophrenic Agents Against Toxoplasma gondii in Human Cell Cultures , 2011, The Journal of parasitology.
[27] M. Widdowson,et al. Foodborne Illness Acquired in the United States—Major Pathogens , 2011, Emerging infectious diseases.
[28] F. Sörgel,et al. Penetration of Drugs through the Blood-Cerebrospinal Fluid/Blood-Brain Barrier for Treatment of Central Nervous System Infections , 2010, Clinical Microbiology Reviews.
[29] D. Rice,et al. Identification and development of novel inhibitors of Toxoplasma gondii enoyl reductase. , 2010, Journal of medicinal chemistry.
[30] D. Roos,et al. Integrative genomic approaches highlight a family of parasite-specific kinases that regulate host responses. , 2010, Cell host & microbe.
[31] R. Yolken,et al. Thiazole, oxadiazole, and carboxamide derivatives of artemisinin are highly selective and potent inhibitors of Toxoplasma gondii. , 2010, Journal of medicinal chemistry.
[32] Anang A. Shelat,et al. Chemical genetics of Plasmodium falciparum , 2010, Nature.
[33] W. de Souza,et al. Toxoplasma gondii: fluconazole and itraconazole activity against toxoplasmosis in a murine model. , 2010, Experimental parasitology.
[34] L. Sibley,et al. Artemisone and Artemiside Control Acute and Reactivated Toxoplasmosis in a Murine Model , 2009, Antimicrobial Agents and Chemotherapy.
[35] A. Teixeira-Carvalho,et al. Innate immunity and regulatory T-cells in human Chagas disease: what must be understood? , 2009, Memorias do Instituto Oswaldo Cruz.
[36] D. Roos,et al. Apicomplexan Parasites Co-Opt Host Calpains to Facilitate Their Escape from Infected Cells , 2009, Science.
[37] G. Toffoli,et al. C677T and A1298C MTHFR polymorphisms, a challenge for antifolate and fluoropyrimidine-based therapy personalisation. , 2009, European journal of cancer.
[38] D. Buxton,et al. Veterinary vaccines against Toxoplasma gondii. , 2009, Memorias do Instituto Oswaldo Cruz.
[39] J. Dubey. The History of Toxoplasma gondii—The First 100 Years , 2008, The Journal of eukaryotic microbiology.
[40] W. de Souza,et al. Itraconazole affects Toxoplasma gondii endodyogeny. , 2008, FEMS microbiology letters.
[41] Mark Noble,et al. Systemic 5-fluorouracil treatment causes a syndrome of delayed myelin destruction in the central nervous system , 2008, Journal of biology.
[42] R. Yolken,et al. Antibodies to Toxoplasma gondii in patients with schizophrenia: a meta-analysis. , 2007, Schizophrenia bulletin.
[43] M. E. Kouni. Adenosine Metabolism in Toxoplasma gondii: Potential Targets for Chemotherapy , 2007 .
[44] R. Yolken,et al. In Vitro Inhibition of Toxoplasma gondii by Four New Derivatives of Artemisinin , 2006, Antimicrobial Agents and Chemotherapy.
[45] Joseph L. DeRisi,et al. Tetracyclines Specifically Target the Apicoplast of the Malaria Parasite Plasmodium falciparum , 2006, Antimicrobial Agents and Chemotherapy.
[46] H. Flynn,et al. In Vitro Antifungal Activity of the Fourth Generation Fluoroquinolones Against Candida Isolates from Human Ocular Infections , 2006, Ocular immunology and inflammation.
[47] D. Peyramond,et al. Prevalence of toxoplasma encephalitis in AIDS patients treated with Didanosine hospitalised in a French infectious service. , 2004, Current HIV research.
[48] D. Lindsay,et al. EFFICACY OF PONAZURIL IN VITRO AND IN PREVENTING AND TREATING TOXOPLASMA GONDII INFECTIONS IN MICE , 2004, The Journal of parasitology.
[49] R. Yolken,et al. Drugs used in the treatment of schizophrenia and bipolar disorder inhibit the replication of Toxoplasma gondii , 2003, Schizophrenia Research.
[50] K. Fujisaki,et al. Growth inhibitory effect of triclosan on equine and bovine Babesia parasites. , 2003, The American journal of tropical medicine and hygiene.
[51] N. Walchshofer,et al. Quinonic derivatives active against Toxoplasma gondii , 2002, Parasitology Research.
[52] J. Boothroyd,et al. An rRNA mutation identifies the apicoplast as the target for clindamycin in Toxoplasma gondii , 2002, Molecular microbiology.
[53] J. E. Hyde,et al. Pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: what next? , 2001, Trends in parasitology.
[54] J. Havlíček,et al. Decrease of psychomotor performance in subjects with latent ‘asymptomatic’ toxoplasmosis , 2001, Parasitology.
[55] R. Lyons,et al. Triclosan inhibits the growth of Plasmodium falciparum and Toxoplasma gondii by inhibition of apicomplexan Fab I. , 2001, International journal for parasitology.
[56] J. Remington,et al. Activity of Gatifloxacin Alone or in Combination with Pyrimethamine or Gamma Interferon against Toxoplasma gondii , 2001, Antimicrobial Agents and Chemotherapy.
[57] L. Weiss,et al. Toxoplasma gondii: from animals to humans. , 2000, International journal for parasitology.
[58] J. Boothroyd,et al. Characterization of cytochrome b from Toxoplasma gondii and Q(o) domain mutations as a mechanism of atovaquone-resistance. , 2000, Molecular and biochemical parasitology.
[59] F. Peyron,et al. Toxoplasma encephalitis: influence of the vehicle on the efficacy of different doses of 2',3'-dideoxyinosine in mice. , 2000, Parasite.
[60] D. Roos,et al. Recombinant expression, purification, and characterization of Toxoplasma gondii adenosine kinase. , 1999, Molecular and biochemical parasitology.
[61] G. Pizzolato,et al. Evaluation of trimethoprim and sulphamethoxazole as monotherapy or in combination in the management of toxoplasmosis in murine models. , 1999, International journal of antimicrobial agents.
[62] J. Remington,et al. Quinupristin-Dalfopristin Is Active againstToxoplasma gondii , 1999, Antimicrobial Agents and Chemotherapy.
[63] F. Peyron,et al. Alterations of Toxoplasma gondii induced by 2',3'-dideoxyinosine in vitro. , 1998, The Journal of parasitology.
[64] T. Slifer,et al. The ketolide antibiotics HMR 3647 and HMR 3004 are active against Toxoplasma gondii in vitro and in murine models of infection , 1997, Antimicrobial agents and chemotherapy.
[65] K. Joiner,et al. Characterization of anti-Toxoplasma activity of SDZ 215-918, a cyclosporin derivative lacking immunosuppressive and peptidyl-prolyl-isomerase-inhibiting activity: possible role of a P glycoprotein in Toxoplasma physiology , 1997, Antimicrobial agents and chemotherapy.
[66] F. Peyron,et al. Effects of 2',3'-dideoxyinosine on Toxoplasma gondii cysts in mice , 1997, Antimicrobial agents and chemotherapy.
[67] T. Slifer,et al. Activity of trovafloxacin in combination with other drugs for treatment of acute murine toxoplasmosis , 1997, Antimicrobial agents and chemotherapy.
[68] H. B. Fung,et al. Treatment regimens for patients with toxoplasmic encephalitis. , 1996, Clinical therapeutics.
[69] F. Derouin,et al. In vitro and in vivo effects of rifabutin alone or combined with atovaquone against Toxoplasma gondii , 1996, Antimicrobial agents and chemotherapy.
[70] J. Remington,et al. Trovafloxacin is active against Toxoplasma gondii , 1996, Antimicrobial agents and chemotherapy.
[71] W. Melchers,et al. Anti-toxoplasma effect of pyrimethamine, trimethoprim and sulphonamides alone and in combination: implications for therapy. , 1996, The Journal of antimicrobial chemotherapy.
[72] J. Remington,et al. Rifapentine is active in vitro and in vivo against Toxoplasma gondii , 1996, Antimicrobial agents and chemotherapy.
[73] S. Queener,et al. Lipophilic antifolates as agents against opportunistic infections. 1. Agents superior to trimetrexate and piritrexim against Toxoplasma gondii and Pneumocystis carinii in in vitro evaluations. , 1996, Journal of medicinal chemistry.
[74] D. Roos,et al. In vitro assays elucidate peculiar kinetics of clindamycin action against Toxoplasma gondii , 1995, Antimicrobial agents and chemotherapy.
[75] D. Lindsay,et al. Treatment of acute Toxoplasma gondii infections in mice with diclazuril or a combination of diclazuril and pyrimethamine. , 1995, The Journal of parasitology.
[76] J. Alder,et al. Treatment of experimental Toxoplasma gondii infection by clarithromycin-based combination therapy with minocycline or pyrimethamine. , 1994, Journal of acquired immune deficiency syndromes.
[77] C. Tinelli,et al. In-vitro and in-vivo activity of rifabutin against Toxoplasma gondii. , 1994, The Journal of antimicrobial chemotherapy.
[78] H. R. Chang,et al. Activity of epiroprim (Ro 11-8958), a dihydrofolate reductase inhibitor, alone and in combination with dapsone against Toxoplasma gondii , 1994, Antimicrobial Agents and Chemotherapy.
[79] D. Lindsay,et al. Activity of diclazuril against Toxoplasma gondii in cultured cells and mice. , 1994, American journal of veterinary research.
[80] T. Slifer,et al. Rifabutin is active in murine models of toxoplasmosis , 1994, Antimicrobial Agents and Chemotherapy.
[81] E. Pfefferkorn,et al. Toxoplasma gondii: susceptibility and development of resistance to anticoccidial drugs in vitro , 1993, Antimicrobial Agents and Chemotherapy.
[82] J. Remington,et al. In vivo activity of the macrolide antibiotics azithromycin, roxithromycin and spiramycin againstToxoplasma gondii , 1991, European Journal of Clinical Microbiology and Infectious Diseases.
[83] H. Kirst,et al. Comparative activity of macrolides against Toxoplasma gondii demonstrating utility of an in vitro microassay , 1991, Antimicrobial Agents and Chemotherapy.
[84] C. Chastang,et al. Anti-Toxoplasma effects of dapsone alone and combined with pyrimethamine , 1991, Antimicrobial Agents and Chemotherapy.
[85] F. Derouin,et al. In vivo assessment of antimicrobial agents against Toxoplasma gondii by quantification of parasites in the blood, lungs, and brain of infected mice , 1990, Antimicrobial Agents and Chemotherapy.
[86] H. R. Chang,et al. In vitro and in vivo effects of doxycycline on Toxoplasma gondii , 1990, Antimicrobial Agents and Chemotherapy.
[87] J. Kovacs,et al. Interaction of sulfonamide and sulfone compounds with Toxoplasma gondii dihydropteroate synthase. , 1990, The Journal of clinical investigation.
[88] J. Kovacs,et al. Potent antipneumocystis and antitoxoplasma activities of piritrexim, a lipid-soluble antifolate , 1988, Antimicrobial Agents and Chemotherapy.
[89] E. Pfefferkorn,et al. Toxoplasma gondii: in vivo and in vitro studies of a mutant resistant to arprinocid-N-oxide. , 1988, Experimental parasitology.
[90] J. Kovacs,et al. Potent in vitro and in vivo antitoxoplasma activity of the lipid-soluble antifolate trimetrexate. , 1987, The Journal of clinical investigation.
[91] B. Luft. Potent in vivo activity of arprinocid, a purine analogue, against murine toxoplasmosis. , 1986, The Journal of infectious diseases.
[92] B. Luft,et al. Activity of roxithromycin (RU 28965), a macrolide, against Toxoplasma gondii infection in mice , 1986, Antimicrobial Agents and Chemotherapy.
[93] B. Luft,et al. The effects of cyclosporine on Toxoplasma gondii in vivo and in vitro. , 1986, Transplantation.
[94] R. McLeod,et al. New micromethod to study the effect of antimicrobial agents on Toxoplasma gondii: comparison of sulfadoxine and sulfadiazine individually and in combination with pyrimethamine and study of clindamycin, metronidazole, and cyclosporin A , 1984, Antimicrobial Agents and Chemotherapy.
[95] E. Hewlett,et al. Antileishmanial activity of chlorpromazine , 1984, Antimicrobial Agents and Chemotherapy.
[96] G. Piekarski. Behavioral alterations caused by parasitic infection in case of latent toxoplasma infection. , 1981, Zentralblatt fur Bakteriologie, Mikrobiologie und Hygiene. 1. Abt. Originale A, Medizinische Mikrobiologie, Infektionskrankheiten und Parasitologie = International journal of microbiology and hygiene. A, Medical microbiology, infectious....
[97] J. Remington,et al. The effect of trimethoprim and sulfamethoxazole on Toxoplasma gondii in vitro and in vivo. , 1979, The American journal of tropical medicine and hygiene.
[98] J. Remington,et al. Effect of Clindamycin on Acute and Chronic Toxoplasmosis in Mice , 1974, Antimicrobial Agents and Chemotherapy.
[99] W. Robinson,et al. The Effect of Rifampin on Toxoplasma gondii 1 , 1970, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.
[100] M. Hokelek,et al. In Vivo Efficacy of Drugs against Toxoplasma gondii Combined with Immunomodulators. , 2016, Japanese journal of infectious diseases.
[101] H. Ramadan,et al. Preventive prospective of triclosan and triclosan-liposomal nanoparticles against experimental infection with a cystogenic ME49 strain of Toxoplasma gondii. , 2015, Acta tropica.
[102] P. G. Saraiva,et al. Current Therapy of Acquired Ocular Toxoplasmosis: A Review. , 2015, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.
[103] M. H. el Kouni. Adenosine metabolism in Toxoplasma gondii: potential targets for chemotherapy. , 2007, Current pharmaceutical design.
[104] J. Maertens,et al. History of the development of azole derivatives. , 2004, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[105] Ph.D. Joseph Heitman M.D.,et al. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases , 2004, Mycopathologia.
[106] F. Peyron,et al. Effects of artesunate, dihydroartemisinin, and an artesunate-dihydroartemisinin combination against Toxoplasma gondii. , 2000, The American journal of tropical medicine and hygiene.
[107] J. Buzby,et al. Economic costs and trade impacts of microbial foodborne illness. , 1997, World health statistics quarterly. Rapport trimestriel de statistiques sanitaires mondiales.
[108] F. Derouin,et al. Effect of immunosuppressive drug regimens on acute and chronic murine toxoplasmosis , 1996, Parasitology Research.
[109] H. Tanowitz,et al. In vitro assessment of antimicrobial agents against Toxoplasma gondii. , 1988, The Journal of infectious diseases.
[110] B. Luft. In vivo and in vitro activity of roxithromycin against Toxoplasma gondii in mice. , 1987, European journal of clinical microbiology.
[111] C. M. Fraser. The Merck veterinary manual. , 1986 .
[112] John E. Bennett,et al. Principles and practice of infectious diseases. Vols 1 and 2. , 1979 .